Last checked at 12 Mar 2019 17:23
Cambridge Cognition Holdings Plc
('Cambridge Cognition' or the 'Company')
Director/PDMR Shareholdings
Further to the Fundraising announced on 7 March 2019, Cambridge Cognition Holdings plc, which develops and markets neuroscience technology to assess brain health, confirms the following disclosures by persons discharging managerial responsibilities.
The information below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
1 | Details of the person discharging managerial responsibilities ("PDMR") / person closely associated ("PCA") | |||||
a) | Name | Steven Powell | ||||
2. | Reason for the Notification | |||||
a) | Position/status | PDMR - Chief Executive Officer | ||||
b) | Initial notification/Amendment | Initial notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Cambridge Cognition Holdings Plc | ||||
b) | LEI | 213800SZKDIN122EPA96 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the Financial instrument, type of instrument | Ordinary Shares of 1 pence each | ||||
Identification code | GB00B8DV9647 | |||||
b) | Nature of the transaction | Subscription for Ordinary Shares | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information: · Aggregated volume
· Price | Subscription for 20,834 ordinary shares at a price of 72p each | ||||
e) | Date of the transaction | 12 March 2019 | ||||
f) | Place of the transaction | London Stock Exchange, AIM Market (XLON) | ||||
1 | Details of the person discharging managerial responsibilities ("PDMR") / person closely associated ("PCA") | |||||
a) | Name | Nick Walters | ||||
2. | Reason for the Notification | |||||
a) | Position/status | PDMR - Chief Financial Officer | ||||
b) | Initial notification/Amendment | Initial notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Cambridge Cognition Holdings Plc | ||||
b) | LEI | 213800SZKDIN122EPA96 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the Financial instrument, type of instrument | Ordinary Shares of 1 pence each | ||||
Identification code | GB00B8DV9647 | |||||
b) | Nature of the transaction | Subscription for Ordinary Shares | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information: · Aggregated volume
· Price | Subscription for 13,889 ordinary shares at a price of 72p each | ||||
e) | Date of the transaction | 12 March 2019 | ||||
f) | Place of the transaction | London Stock Exchange, AIM Market (XLON) | ||||
Enquiries
Cambridge Cognition Holdings PLC Steven Powell, Chief Executive Officer Nick Walters, Chief Financial Officer
|
Tel: 01223 810 700 press@camcog.com |
finnCap Ltd (NOMAD and Joint Broker) Geoff Nash / Simon Hicks Alice Lane / Manasa Patil
| Tel: 020 7220 0500 (Corporate Finance) (Corporate Broking) |
Dowgate Capital Limited (Joint Broker) David Poutney / James Serjeant
| Tel: 020 3903 7715
|
IFC Advisory Ltd (Financial PR and IR) Graham Herring / Miles Nolan / Zach Cohen | Tel: 020 3934 6630
|
About Cambridge Cognition
Cambridge Cognition is a neuroscience technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early, and reduce global R&D and healthcare costs.
For further information visit www.cambridgecognition.com